Tiba Biotech announced its new partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), through initiation of an EZ-BAA contract to develop groundbreaking therapeutics against influenza.

We are excited to receive this BARDA award, which will advance Tiba’s innovative approach to combating influenza and other viral threats. We believe our technology has the potential to transform the landscape of RNA therapeutics..

— Jusdave Chahal, co-founder and lead investigator of the project

For more, see the Tiba Biotech press release.